Skip to Content

'
Khalid A. Mohamedali, Ph.D.

Present Title & Affiliation

Primary Appointment

Instructor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1994 Rice University, Houston, TX, PHD, Biochemistry
1987 Texas A&M University, College Station, TX, BS, Biochemistry

Experience/Service

Institutional Committee Activities

Judge, Trainee Research Day, 2008-2012
Committee Member, Department of Experimental Therapeutics Research Seminar Series Committee, 11/2005-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Weyergang A, Cheung LH, Rosenblum MG, Mohamedali KA, Peng Q, Waltenberger J, Berg K. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF121/rGel fusion toxin. J Control Release 180:1-9, 4/2014. e-Pub 2/2014. PMID: 24531010.
2. Mohamedali KA, Cao Y, Cheung LH, Hittelman WN, Rosenblum MG. The Functionalized Human Serine Protease Granzyme B/VEGF121 Targets Tumor Vasculature and Ablates Tumor Growth. Molecular Cancer Therapeutics 12(10):2055-66, 10/2013. PMCID: PMC3921020.
3. Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SAN, Cheng E, Weiss MB, Hittelman WN, Tran NH, Yagita H, Winkles JA, Rosenblum MG. The TWEAK Receptor Fn14 Is a Novel Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment. Journal of Investigative Dermatology 133(4):1052-62, 4/2013. PMCID: PMC3600159.
4. Cao Y, Mohamedali KA, Marks JW, Cheung LH, Hittelman WN, Rosenblum MG. Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu. Molecular Cancer Therapeutics 12(6):979-91, 2013 Jun, 3/2013. e-Pub 3/2013. PMID: 23493312.
5. Zhang F, Huang X, Zhu L, Guo N, Niu G, Swierczewska M, Lee S, Xu H, Wang AY, Mohamedali KA, Rosenblum MG, Lu G, Chen X. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials 33(21):5414, 7/2012. PMCID: PMC3577933.
6. Mohamedali KA, Niu G, Luster TA, Thorpe PE, Gao H, Chen X, Rosenblum MG. Pharmacodynamics, Tissue Distribution, Toxicity Studies and Antitumor Efficacy of the Vascular Targeting Fusion Toxin VEGF121/rGel. Biochemical Pharmacology 84(11):1534-40, 2012. e-Pub 9/2012. PMID: 23022224.
7. Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG. Cytotoxicity of VEGF121/rGel on Vascular Endothelial Cells Resulting in Inhibition of Angiogenesis is Mediated via VEGFR-2. BMC Cancer 11(1):358, 8/2011. PMCID: PMC3176242.
8. Berlin JM, Pham TT, Sano D, Mohamedali KA, Marcano DC, Myers JN, Tour JM. Non-Covalent Functionalization of Carbon Nanovectors with an Antibody Enables Targeted Drug Delivery. ACS Nano 5(8):6643-50, 8/2011. e-Pub 7/2011. PMCID: PMC3160510.
9. Cho EJ, Yang J, Mohamedali KA, Lim EK, Kim EJ, Farhangfar CJ, Suh JS, Haam S, Rosenblum MG, Huh YM. Sensitive Angiogenesis Imaging of Orthotopic Bladder Tumors in Mice Using a Selective Magnetic Resonance Imaging Contrast Agent Containing VEGF121/rGel. Invest Radiol 46(7):441-9, 7/2011. PMID: 21512397.
10. Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone NM. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res 17(8):2328-38, 4/2011. e-Pub 2/2011. PMCID: PMC3078947.
11. Yang M, Gao H, Sun X, Yan Y, Quan Q, Zhang W, Mohamedali KA, Rosenblum MG, Niu G, Chen X. Multiplexed PET Probes for Imaging Breast Cancer Early Response to VEGF121/rGel Treatment. Mol Pharm 8(2):621-8, 4/2011. e-Pub 2/2011. PMCID: PMC3070817.
12. Zhou H, Liu Y, Cheung LH, Kim S, Zhang W, Mohamedali KA, Anand P, Hittelman WN, Aggarwal BB, Rosenblum MG. Characterization and Mechanistic Studies of a Novel Melanoma-targeting Construct Containing IκBα for Specific Inhibition of NF-κB Activity. Neoplasia 12(10):766-77, 10/2010. PMCID: PMC2950326.
13. Rodriguez-Porcel M, Cai W, Gheysens O, Willmann JK, Chen K, Wang H, Chen IY, He L, Wu JC, Li ZB, Mohamedali KA, Kim S, Rosenblum MG, Chen X, Gambhir SS. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med 49(4):667-73, 4/2008. PMCID: PMC2853914.
14. Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S, Vogel H, Hou LC, Tse V, Rosenblum MG, Chen X. Multimodality Molecular Imaging of Glioblastoma Growth Inhibition with Vasculature-Targeting Fusion Toxin VEGF121/rGel. J Nucl Med 48(3):445-454, 3/2007. PMID: 17332623.
15. Kim S, Mohamedali KA, Cheung LH, Rosenblum MG. Overexpression of biologically active VEGF(121) fusion proteins in Escherichia coli. J Biotechnol 128(3):638-47, 2/2007. PMID: 17218033.
16. Cai W, Chen K, Mohamedali KA, Cao Q, Gambhir SS, Rosenblum MG, Chen X. PET of vascular endothelial growth factor receptor expression. J Nucl Med 47(12):2048-56, 12/2006. PMID: 17138749.
17. Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res 66(22):10919-28, 11/2006. PMID: 17108129.
18. Akiyama H, Mohamedali KA, Silva RL, Kachi S, Shen J, Hatara C, Umeda N, Hackett SF, Aslam S, Krause M, Lai H, Rosenblum MG, Campochiaro PA. Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein. Mol Pharmacol 68(6):1543-50, 12/2005. PMID: 16150930.
19. Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia 7(10):912-20, 10/2005. PMID: 16242074.
20. Ran S, Mohamedali KA, Luster TA, Thorpe PE, Rosenblum MG. The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia 7(5):486-96, 5/2005. PMID: 15967101.
21. Wang F, Lu W, McKeehan K, Mohamedali K, Gabriel JL, Kan M, McKeehan WL. Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex. Biochemistry 38(1):160-71, 1/1999. PMID: 9890894.
22. Luo Y, Lu W, Mohamedali KA, Jang JH, Jones RB, Gabriel JL, Kan M, McKeehan WL. The glycine box: a determinant of specificity for fibroblast growth factor. Biochemistry 37(47):16506-15, 11/1998. PMID: 9843417.
23. Timchenko NA, Wilde M, Kosai KI, Heydari A, Bilyeu TA, Finegold MJ, Mohamedali K, Richardson A, Darlington GJ. Regenerating livers of old rats contain high levels of C/EBPalpha that correlate with altered expression of cell cycle associated proteins. Nucleic Acids Res 26(13):3293-9, 7/1998. PMID: 9628932.
24. Sideraki V, Mohamedali KA, Wilson DK, Chang Z, Kellems RE, Quiocho FA, Rudolph FB. Probing the functional role of two conserved active site aspartates in mouse adenosine deaminase. Biochemistry 35(24):7862-72, 6/1996. PMID: 8672487.
25. Mohamedali KA, Kurz LC, Rudolph FB. Site-directed mutagenesis of active site glutamate-217 in mouse adenosine deaminase. Biochemistry 35(5):1672-80, 2/1996. PMID: 8634299.
26. Mohamedali KA, Guicherit OM, Kellems RE, Rudolph FB. The highest levels of purine catabolic enzymes in mice are present in the proximal small intestine. J Biol Chem 268(31):23728-33, 11/1993. PMID: 8226898.

Last updated: 6/11/2014